| 09.07.2025 09:47 | IPX, CRH, GFRD | LONDON BROKER RATINGS: Jefferies says buy BAT and Imperial Brands | Alliance |
| 04.07.2025 17:19 | AZN | CORRECT: AstraZeneca bladder cancer treatment secures EU approval
| Alliance |
| 04.07.2025 08:02 | AZN | AstraZeneca bladder cancer treatment Imfinzi secures EU approval
| Alliance |
| 04.07.2025 07:00 | AZN | Imfinzi approved in the EU for bladder cancer | RNS |
| 03.07.2025 09:45 | RBW, RSG, PAF | LONDON BROKER RATINGS: Berenberg cuts Rio Tinto; UBS cuts Fresnillo | Alliance |
| 01.07.2025 17:43 | AZN | PRESS: AstraZeneca CEO Soriot wants to move listing to the US - Times | Alliance |
| 01.07.2025 15:00 | AZN | Total Voting Rights | RNS |
| 24.06.2025 07:00 | AZN | Datroway approved in US for EGFRm lung cancer | RNS |
| 17.06.2025 11:45 | AZN, NIOX | Holding(s) in Company | RNS |
| 13.06.2025 10:19 | AZN | AstraZeneca boosts China ties with up to USD5.3 billion partnership | Alliance |
| 13.06.2025 09:30 | AZN | AstraZeneca enters into collaboration with CSPC | RNS |
| 12.06.2025 15:00 | AZN | Director/PDMR Shareholding | RNS |
| 06.06.2025 09:02 | AZN | AstraZeneca's Calquence gets EU nod to treat adults with leukaemia | Alliance |
| 06.06.2025 07:00 | AZN | Fixed-duration Calquence approved in EU for 1L CLL | RNS |
| 02.06.2025 15:05 | AZN | Block listing Interim Review | RNS |
| 02.06.2025 15:00 | AZN | Total Voting Rights | RNS |
| 02.06.2025 14:23 | AZN | AstraZeneca says Enhertu slashes disease progression risk in cancer | Alliance |
| 02.06.2025 11:19 | HCM, AZN | Hutchmed reports progress in late-stage lung cancer trial | Alliance |
| 02.06.2025 06:45 | AZN | AstraZeneca hails Imfinzi results on early stage gastric cancer | Alliance |
| 30.05.2025 10:08 | AZN | Danaher partners with AstraZeneca to develop AI diagnostics | Alliance |
| 28.05.2025 13:31 | AGL, AZN | Angle shares fall on weak 2025 outlook despite narrower annual loss | Alliance |
| 28.05.2025 09:36 | AGL, S32, ELM | LONDON BROKER RATINGS: RBC cuts National Grid; Citigroup cuts South32 | Alliance |
| 27.05.2025 08:36 | AZN | AstraZeneca bladder cancer drug Imfinzi recommended for EU approval | Alliance |
| 27.05.2025 07:00 | AZN | Imfinzi recommended in EU for bladder cancer | RNS |
| 23.05.2025 10:00 | AZN | Director/PDMR Shareholding | RNS |
| 21.05.2025 14:28 | AZN | IN BRIEF: AstraZeneca chief executive joins Agilent Technologies board | Alliance |
| 21.05.2025 13:45 | AZN | Director Declaration | RNS |
| 20.05.2025 08:55 | AZN | AstraZeneca completes EsoBiotec acquisition for up to USD1 billion | Alliance |
| 20.05.2025 07:00 | AZN | Acquisition of EsoBiotec completed | RNS |
| 19.05.2025 19:54 | AZN | IN BRIEF: AstraZeneca trial shows Airsupra effective against asthma | Alliance |
| 12.05.2025 09:09 | AZN | AstraZeneca gets UK approval for Trixeo with eco-friendly propellant | Alliance |
| 09.05.2025 09:29 | AZN | AstraZeneca receives positive bladder cancer trial data for Imfinzi | Alliance |
| 09.05.2025 07:00 | AZN | Imfinzi improved DFS in early bladder cancer | RNS |
| 07.05.2025 09:33 | AZN | AstraZeneca touts positive trial data for breast cancer treatment | Alliance |
| 07.05.2025 07:30 | AZN | Enhertu improved pCR in early-stage breast cancer | RNS |
| 06.05.2025 09:41 | AZN | AstraZeneca's Calquence gets EU approval to treat adults with MCL | Alliance |
| 06.05.2025 07:00 | AZN | Calquence combination approved in EU for 1L MCL | RNS |
| 02.05.2025 10:03 | AZN | AstraZeneca asthma drug meets targets in phase 3 trials | Alliance |
| 02.05.2025 07:00 | AZN | Breztri met primary endpoints in Ph3 asthma trials | RNS |
| 01.05.2025 16:00 | AZN | Director/PDMR Shareholding | RNS |
| 01.05.2025 15:00 | AZN | Total Voting Rights | RNS |
| 01.05.2025 09:33 | TTG, DATA, JET2 | LONDON BROKER RATINGS: Deutsche Bank, Deutsche Numis raise GlobalData | Alliance |
| 29.04.2025 09:29 | AZN | AstraZeneca confirms annual guidance ahead of "catalyst-rich period" | Alliance |
| 29.04.2025 07:10 | AZN | Fixed-duration Calquence recommended in EU for CLL | RNS |
| 29.04.2025 07:05 | AZN | Update on CAPItello-280 Phase III trial | RNS |
| 29.04.2025 07:00 | AZN | 1st Quarter Results | RNS |
| 28.04.2025 09:26 | CWR, CHRT, AMS | LONDON BROKER RATINGS: Berkeley and Advanced Medical Solutions raised | Alliance |
| 22.04.2025 16:59 | W7L, TPK, TST | UK earnings, trading statements calendar - next 7 days | Alliance |
| 22.04.2025 08:32 | AZN, HCM | Hutchmed China completes enrolment for gastric cancer drug trial | Alliance |
| 22.04.2025 07:00 | AZN | Enhertu combination improved PFS in 1L HER2+ mBC | RNS |
| 11.04.2025 17:30 | AZN | Result of AGM | RNS |
| 09.04.2025 10:08 | CAML, TSTL, BHP | LONDON BROKER RATINGS: Kepler raises Rolls-Royce; UBS cuts ITV | Alliance |
| 09.04.2025 05:58 | AZN | Daiichi Sankyo and AstraZeneca secure EU approval for Datroway | Alliance |
| 04.04.2025 14:16 | JADE, AZN | UK shareholder meetings calendar - next 7 days | Alliance |
| 04.04.2025 09:44 | AZN | AstraZeneca gets EU approval for cancer treatments Enhertu and Imfinzi | Alliance |
| 04.04.2025 07:05 | AZN | Imfinzi approved in EU for AEGEAN | RNS |
| 04.04.2025 07:00 | AZN | Enhertu approved in EU in post-ET breast cancer | RNS |
| 01.04.2025 15:00 | AZN | Total Voting Rights | RNS |
| 31.03.2025 09:43 | AZN | AstraZeneca reports positive developments with assets in US and EU | Alliance |
| 31.03.2025 07:05 | AZN | Calquence recommended for EU approval in 1L MCL | RNS |
| 31.03.2025 07:00 | AZN | Imfinzi approved in the US for bladder cancer | RNS |
| 28.03.2025 09:22 | SUPR, VTY, BRBY | LONDON BROKER RATINGS: Next gets price target bumps after results | Alliance |
| 25.03.2025 09:04 | AZN | AstraZeneca highlights new Tagrisso data in lung cancer trials
| Alliance |
| 21.03.2025 14:25 | AGL, AZN | Angle hails successful completion of Eisai contract; approval by Astra | Alliance |
| 21.03.2025 11:27 | AZN | AstraZeneca to invest USD2.5 billion in new Beijing strategic centre | Alliance |
| 21.03.2025 10:58 | AZN | AZN invests $2.5bn in Beijing R&D & manufacturing | RNS |
| 20.03.2025 14:31 | AZN, HCM | IN BRIEF: Hutchmed highlights positive lung cancer test results | Alliance |
| 17.03.2025 14:22 | SHEL, AZN, PUAL | UK dividends calendar - next 7 days | Alliance |
| 17.03.2025 08:57 | AZN | AstraZeneca to pay up to USD1 billion for cell therapy firm, EsoBiotec | Alliance |
| 17.03.2025 07:10 | AZN | Eneboparatide Phase III trial met primary endpoint | RNS |
| 17.03.2025 07:05 | AZN | Imfinzi approved in EU for limited-stage SCLC | RNS |
| 17.03.2025 07:00 | AZN | AstraZeneca to acquire EsoBiotec | RNS |
| 12.03.2025 18:00 | AZN | Holding(s) in Company | RNS |
| 07.03.2025 15:00 | AZN | Director/PDMR Shareholding | RNS |
| 07.03.2025 11:00 | AZN | Notice of AGM | RNS |
